- Webinar Speakers
Dr. Kumar Prabhash
Professor, Medical Oncology, Tata Memorial Hospital, IndiaDr. Kumar is a professor and medical oncologist in Tata Memorial Hospital and has more than two decades of experience. He is the present President and convener of Indian Cooperative Oncology Network (ICON). He has so far published over a hundred research and review articles/papers in journals of national and international repute. He has so far undertaken over 80 projects as Principal Investigator and Co-Investigator.
He is a member of many international and national scientific societies and associations and has delivered talks in several conferences. These days he is proactive in increasing awareness about lung cancer and has successfully conceptualized Lung Cancer Consortium Asia, he has significantly contributed in translational and clinical research work in the field of lung cancer and has published 17 papers in recent years. He is dedicated to create awareness about lung cancer with utmost importance to patient care and to strengthen future research.
Dr. Anuradha Chougule
Professor and Senior Scientist, Tata Memorial Center, IndiaDr. Chougule received her PhD from the Bhabha Atomic Research Centre in Mumbai University. She is an innovative, accomplished molecular geneticist with 30+ years of experience in research and molecular diagnostics. She is currently focusing on “Bench to Bedside” applications at the prestigious Tata Memorial Center, an advanced center for treatment, research and education in Cancer.
Dr. Chougule has over 55+ research publications in international and Indian scientific journals. She has also received many faculty invitations and given more than 50+ oral presentations at national and international forums.
- Webinar Abstract
Liquid biopsy is an alternative to tissue biopsy and can play a major role in cancer targeted therapy, predominantly in NSCLC. New biopsy is required in NSCLC progressed patients to determine resistance mechanism. Re-biopsy is a challenge. Tissue vs liquid biopsy results are highly concordant however, 30% false negative result reported. Clinical utility of liquid biopsy (ctDNA) has been established in several clinical trials. Monitoring of molecular resistance in tumor is possible through liquid biopsy (ctDNA). Dynamic changes in disease molecular profile can be determined by liquid biopsy. Highly sensitive and validated method should be employed to correctly genotype the tumor. Thus liquid biopsy tests may offer an easier way to spot cancer's footprints.